Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin

Diabetes Care

Volumn 24, Issue 4, 2001, Pages 631-636

  Rosenstock, Julio ^a   Schwartz, Sherwyn L ^b   Clark Jr , Charles M ^c   Park, Glen D ^d   Donley, David W ^e   Edwards, Mike B ^e  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Diabetes and Glandular Disease Research Center   (United States)

^c REGENSTRIEF INSTITUTE   (United States)

^d Ingenix Inc   (United States)

^e IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RISK FACTOR; TREATMENT PLANNING; WEIGHT GAIN;

EID: 0034827469     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.4.631     Document Type: Article

References (18)

1. Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years
2. Overview of 6 years' therapy of type II diabetes, a progressive disease
3. Intensive insulin therapy prevents the progression of diabetic microvascular in complications Japanese patients with non-insulin-dependent diabetes mellitus: A randomized, prospective 6-year study
4. A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
5. Insulin analogues
6. New directions in drug development: Mixtures, analogs, and modeling
7. Improving insulin therapy: Achievements and challenges
8. Insulin analogues and their potential in the management of diabetes mellitus
9. Controlling insulin bioavailability by crystal contact engineering
10. New insulin preparations with prolonged action profiles: A21-modified arginine insulins
11. HOE 901: A new insulin with prolonged action
12. Pharmacokinetics of a 'long-acting' human insulin analogue (HOE 901) in healthy subjects
13. Efficacy of HOE 901 following subcutaneous injection for four days in type I diabetic subjects
14. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
15. Efficacy and safety of HOE 901 versus NPH insulin in patients with type I diabetes
16. The effect of HOE 901 on glycemic control in type 2 diabetes
17. Comparative clinical trial of a new long-acting insulin (HOE901) vs. protamine insulin demonstrates less nocturnal hypoglycaemia
18. Less nocturnal hypoglycemia and better post-dinner glocose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination theraphy in type 2 diabetes